Tech & Pharma

CEL-SCI’s Phase III Trial Enrols Patients From Sri Lanka CEL-SCI’s Phase III Trial Enrols Patients From Sri Lanka
  • July 25th, 2014
  • CEL-SCI has begun enrolling patients from Sri Lanka for a Phase III trial for Multikine, an investigational treatment for head and neck cancer.

» Read More...

Tech & Pharma

CEL-SCI’s Phase III Trial Enrols Patients From Sri Lanka

CEL-SCI’s Phase III Trial Enrols Patients From Sri Lanka

CEL-SCI has begun enrolling patients from Sri Lanka for a Phase III trial for Multikine, an investigational treatment for head and neck cancer.

Tata Communications To Invest US$200 Million In India Data Center

Tata Communications To Invest US$200 Million In India Data Center

Tata Communication’s US$200 million investment will double the capacity of its data center in New Delhi.

KAIST Develops Two-Sided Touchable Display, TransWall

KAIST Develops Two-Sided Touchable Display, TransWall

The two-sided, transparent TransWall developed at KAIST provides users with interactive haptic feedback.

ISRO Earned US$54 Million From Foreign Launches

ISRO Earned US$54 Million From Foreign Launches

Launching satellites for countries including Japan and Singapore has earned the Indian Space Research Organization US$54 million in the last three years.

Luye Raises US$764 Million With Hong Kong IPO

Luye Raises US$764 Million With Hong Kong IPO

Luye Pharma has raised US$764 million through an IPO on the Main Board of the Stock Exchange of Hong Kong.

BGI’s Down Syndrome Test Gets CFDA Approval

BGI’s Down Syndrome Test Gets CFDA Approval

In a reversal of a previous ruling banning clinical genetic testing, the CFDA has approved BGI’s prenatal testing kits.

BITS Pilani Develops Rapid Antibiotic Test Kit

BITS Pilani Develops Rapid Antibiotic Test Kit

A portable antibiotic tester invented at BITS Pilani, Hyderabad will be commercially developed by a university spin-off company xBITS.

NTU Launches Nano & Pico Satellites

NTU Launches Nano & Pico Satellites

Designed and built by students and researchers at NTU, the satellites VELOX-I and VELOX-PIII are now orbiting 650 km above the Earth.

Phase I Trial For BeiGene’s PARP Inhibitor Begins

Phase I Trial For BeiGene’s PARP Inhibitor Begins

BeiGene’s PARP inhibitor BGB-290 could be an important treatment for common cancers such as gastric cancer and primary brain tumors.

Sanofi & Takeda Partner For Diabetes

Sanofi & Takeda Partner For Diabetes

The partnership between Sanofi and Takeda aims to raise diabetes awareness and provide educational support for both patients and healthcare professionals.